{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:50:33Z","timestamp":1785898233635,"version":"3.56.0"},"reference-count":46,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T00:00:00Z","timestamp":1509667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"NIH\/NCI","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:p>Hepatitis C virus (HCV) causes a chronic but curable infection associated with the development of marginal zone lymphoma (MZL) and diffuse large B\u2010cell lymphoma (DLBCL). Preliminary data have shown frequent transformation of indolent lymphoma to DLBCL in HCV\u2010infected patients. To compare their clinicopathologic characteristics and oncologic outcomes, we reviewed the medical records and pathology reports of HCV\u2010infected and uninfected patients with DLBCL that transformed from indolent lymphoma seen at The University of Texas MD Anderson Cancer Center (June 2004 to May 2015). To identify predictors of DLBCL relapse, patients with relapse after first\u2010line chemotherapy were compared with those without it using univariate and logistic regression analyses. Compared with the uninfected patients (<jats:italic>n<\/jats:italic>\u2009=\u200963), HCV\u2010infected patients (<jats:italic>n<\/jats:italic>\u2009=\u200921) were younger (median age =54 years [interquartile range= 49\u201362 years] <jats:italic>vs<\/jats:italic>. 62 years [53\u201366 years]; <jats:italic>p<\/jats:italic>\u2009=\u20090.01) and more often had advanced DLBCL (Ann Arbor stage 3\u20134; 95% <jats:italic>vs<\/jats:italic>. 76%; <jats:italic>p<\/jats:italic>\u2009=\u20090.05). Immunophenotypically, more HCV\u2010infected than uninfected patients had CD10\u2010negative B cells (76% <jats:italic>vs<\/jats:italic>. 43%; <jats:italic>p<\/jats:italic>\u2009=\u20090.008), CD5\u2010positive B cells (39% <jats:italic>vs<\/jats:italic>. 7%; <jats:italic>p<\/jats:italic>\u2009=\u20090.004) and activated B\u2010cell phenotypes (57% <jats:italic>vs<\/jats:italic>. 31%; <jats:italic>p<\/jats:italic>\u2009=\u20090.07). Comparison of the patients who had relapse after first\u2010line chemotherapy (<jats:italic>n<\/jats:italic>\u2009=\u200942) and those who did not (<jats:italic>n<\/jats:italic>\u2009=\u200940) revealed that having CD5\u2010positive B cells was the only factor associated with DLBCL relapse in multivariate analysis (odds ratio= 10.7; <jats:italic>p<\/jats:italic>\u2009=\u20090.02). HCV\u2010infected patients with transformed DLBCL have unique clinicopathologic characteristics that make their lymphoma difficult to treat, potentially leading to unfavorable outcome. The impact of HCV eradication should be explored in such patients.<\/jats:p>","DOI":"10.1002\/ijc.31110","type":"journal-article","created":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T07:00:37Z","timestamp":1508396437000},"page":"940-948","source":"Crossref","is-referenced-by-count":15,"title":["Clinicopathologic characteristics and outcomes of transformed diffuse large <scp>B<\/scp>\u2010cell lymphoma in hepatitis <scp>C<\/scp> virus\u2010infected patients"],"prefix":"10.1002","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4193-1587","authenticated-orcid":false,"given":"Jeff","family":"Hosry","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto N.","family":"Miranda","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4625-421X","authenticated-orcid":false,"given":"Minas P.","family":"Economides","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrys A.","family":"Torres","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center Houston TX"},{"name":"Department of Gastroenterology, Hepatology and Nutrition The University of Texas MD Anderson Cancer Center Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,3]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21403"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(16)30143-7"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.551573"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.02.011"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.03.018"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3230"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.10.4296.bloodjournal87104296"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29845"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25499"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3745"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-714667"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013376"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-618652"},{"key":"e_1_2_8_15_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines. Non\u2010Hodgkin's Lymphomas). Version 3.2017.http:\/\/www.nccn.org. Accessed on June 5 2017."},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7577"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1587"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07166.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1309\/R01VXG46MFCDVNHL"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.53.3.187"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000561"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.5016"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl131"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30372"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.3260"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/980942"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2006.02063.x"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109099348"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/105.1.31"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.011049"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3105057"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009748809096744"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310509"},{"issue":"13","key":"e_1_2_8_36_1","first-page":"S109","article-title":"Relationship between rheumatoid factor and the immune response against hepatitis C virus in essential mixed cryoglobulinemia","volume":"13","author":"Pietrogrande M","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23467"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-015-1845-1"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.09.012"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06956-11"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80198-1"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00122-3"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00075-8"},{"key":"e_1_2_8_44_1","doi-asserted-by":"crossref","unstructured":"TorresHA EconomidesMP KyvernitakisA et al. Sofosbuvir\u2010based therapy in patients with chronic Hepatitis c virus infection and malignancies\u2014a prospective observational study of 143 patients. In The 53rd Annual Meeting of American Society of Clinical Oncology (ASCO) Chicago IL June 2017.","DOI":"10.1200\/JCO.2017.35.15_suppl.e18152"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718643"},{"key":"e_1_2_8_46_1","first-page":"22167","article-title":"Association of risk of non\u2010Hodgkin's lymphoma with hepatitis B virus infection: a meta\u2010analysis","volume":"8","author":"Qi Z","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.12.010"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.31110","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.31110","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.31110","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.31110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T08:49:34Z","timestamp":1694422174000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.31110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,3]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1002\/ijc.31110"],"URL":"https:\/\/doi.org\/10.1002\/ijc.31110","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,3]]}}}